surmount-1 tirzepatide trial obesity without diabetes once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Tirzepatide on ingestive behavior in

In clinical trials, tirzepatide was shown to be effective in helping overweight adults with at least one associated health problem lose weight

Limitations & Considerations The enrolled participants with obesity and overweight may represent a subpopulation with a greater commitment to weight-management efforts than the general population with obesity The measured baseline cardiometabolic risk factors in the trial population, such as blood pressure and lipids, were relatively normal, possibly attenuating the potential to show improvement, though meaningful changes in these variables were observed

EHCNYC PROGRAM MEMBER John F Elite Health Center team is amazing

Sorimachi H, Obokata M, Takahashi N, et al

Clinical studies have demonstrated that participants using tirzepatide achieved substantial weight lossup to 15 to 20 percent of their total body weight over 72 weeks

Image New Africa/shutterstock.com